Dexcom (DXCM)DSM Capital Partners LLC reduced its stake -565K shares

1.36M

Shares reported · -565K vs prior quarter

1.6%

Disclosed portfolio weight

$91.5M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 3, 2026InsiderOfficer sold ~$359K of DXCM shares in the open market
2. Jun 4, 2026InsiderOfficer sold ~$364K of DXCM shares in the open market
3. Jun 8, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System
4. Jun 12, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
5. Jun 15, 2026Insider · 2 peopleInsiders: 3 sales (~$425K)
6. Jul 6, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
7. Jul 15, 2026InsiderOfficer sold ~$127K of DXCM shares in the open market
8. Jul 20, 2026InsiderChair sold ~$2.04M of DXCM shares in the open market
9. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
10. Jul 31, 2026InsiderDirector sold ~$160K of DXCM shares in the open market
11. Aug 3, 2026InsiderDirector sold ~$171K of DXCM shares in the open market

What came next

1. Aug 11, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
2. Aug 12, 2026InsiderDirector sold ~$89K of DXCM shares in the open market
3. Aug 14, 2026InsiderOfficer sold ~$156K of DXCM shares in the open market
4. Aug 20, 2026Insider · 1 personInsiders: 3 sales (~$2.4M)
5. Aug 27, 2026InsiderOfficer sold ~$227K of DXCM shares in the open market
6. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.”
7. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.”
8. Sep 10, 2026InsiderOfficer sold ~$303K of DXCM shares in the open market
9. Sep 14, 2026InsiderDirector sold ~$130K of DXCM shares in the open market
10. Sep 15, 2026Insider · 2 peopleInsiders: 2 sales (~$692K)
11. Sep 28, 2026InsiderOfficer sold ~$221K of DXCM shares in the open market

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

How this filing works

• SEC Form 13F

Other disclosures at Dexcom

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026

Everything OQRO holds on this company is on its DXCM page.